Last update: July 1, 2015
Minimal risk for breastfeeding and infant.
It is excreted into breast milk in non-significant amount. Plasma level in infants from mother who receive Fluvoxamine is usually undetectable. Not effects on the infant's physical and psychomotor development at both short or long-term were found.
Because there is less experience published than with other antidepressants of the same pharmacological group, it should be preferred the use of an alternative drug that is known to be safer in the neonatal period or prematurity.
Galactorrhea has been observed but less frequently than with other antidepressants.
In cases of treatment with xanthines (theophylline, caffeine) for apnea of prematurity, the plasma level of them should be monitored because Fluvoxamine is a strong inhibitor of activity of the Cytochrome P450-CYP1A2 which is responsible for metabolic elimination of xanthines.
Women who use antidepressant medication during pregnancy are in need of more support for breastfeeding since they are at risk for early weaning.
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana from Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM